Clovis Oncology Inc. (NASDAQ: CLVS) is -50.98% lower on its value in year-to-date trading and has touched a low of $2.93 and a high of $17.37 in the current 52-week trading range. The CLVS stock was last observed hovering at around $4.96 in the last trading session, with the day’s gains setting it 0.15% off its average median price target of $6.00 for the next 12 months. It is also 77.78% off the consensus price target high of $23.00 offered by 9 analysts, but current levels are -27.75% lower than the price target low of $4.00 for the same period.
Currently trading at $5.11, the stock is -7.19% and -17.50% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.26 million and changing 3.02% at the moment leaves the stock -35.10% off its SMA200. CLVS registered -10.82% loss for a year compared to 6-month loss of -32.14%. The firm has a 50-day simple moving average (SMA 50) of $5.90 and a 200-day simple moving average (SMA200) of $7.00.
The stock witnessed a -16.09% gain in the last 1 month and extending the period to 3 months gives it a -26.16%, and is -7.26% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.96% over the week and 7.31% over the month.
Clovis Oncology Inc. (CLVS) has around 484 employees, a market worth around $469.46M and $159.40M in sales. Distance from 52-week low is 74.40% and -70.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-76.50%).
Clovis Oncology Inc. (CLVS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Clovis Oncology Inc. (CLVS) is a “Hold”. 9 analysts offering their recommendations for the stock have an average rating of 3.10, where 4 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
Clovis Oncology Inc. is expected to release its quarterly report on 10/28/2020.The EPS is expected to shrink by -5.20% this year.
Clovis Oncology Inc. (CLVS) Top Institutional Holders
204 institutions hold shares in Clovis Oncology Inc. (CLVS), with 2M shares held by insiders accounting for 2.27% while institutional investors hold 49.58% of the company’s shares. The shares outstanding are 87.99M, and float is at 85.08M with Short Float at 39.86%. Institutions hold 48.46% of the Float.
The top institutional shareholder in the company is State Street Corporation with over 9.24 million shares valued at $62.36 million. The investor’s holdings represent 10.47% of the CLVS Shares outstanding. As of Jun 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 6.24 million shares valued at $42.15 million to account for 7.08% of the shares outstanding. The other top investors are Blackrock Inc. which holds 5.62 million shares representing 6.38% and valued at over $37.96 million, while Palo Alto Investors Lp holds 4.94% of the shares totaling 4.36 million with a market value of $29.44 million.
Clovis Oncology Inc. (CLVS) Insider Activity
A total of 62 insider transactions have happened at Clovis Oncology Inc. (CLVS) in the last six months, with sales accounting for 31 and purchases happening 31 times. The most recent transaction is an insider sale by MUEHL DANIEL W. SEC filings show that MUEHL DANIEL W sold 242 shares of the company’s common stock on Aug 26 at a price of $5.07 per share for a total of $1227.0. Following the sale, the insider now owns 30477.0 shares.
Clovis Oncology Inc. disclosed in a document filed with the SEC on Aug 03 that Gross Paul Edward sold a total of 2,506 shares of the company’s common stock. The trade occurred on Aug 03 and was made at $5.92 per share for $14836.0. Following the transaction, the insider now directly holds 24732.0 shares of the CLVS stock.
Still, SEC filings show that on Aug 03, IVERS-READ GILLIAN C disposed off 1,670 shares at an average price of $5.92 for $9886.0. The insider now directly holds 210,934 shares of Clovis Oncology Inc. (CLVS).
Clovis Oncology Inc. (CLVS): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 34.24% up over the past 12 months. Johnson & Johnson (JNJ) is 18.88% up on the 1-year trading charts. Short interest in the company’s stock has risen 9.58% from the last report on Jul 14, 2020 to stand at a total of 32.65 million short shares sold with a short interest ratio of 8.57.